Another insulin will be on the market, intensifying market competition is inevitable

Diabetes is a chronic metabolic disease that is caused by the influence of genetic factors, environmental factors and living habits, and seriously threatens human health
.
In recent years, due to changes in life>
.
Affected by this, the field of corresponding therapeutic drugs is gradually becoming a huge market, attracting more and more companies to join the game
.
Recently, Hisun Pharmaceuticals issued an announcement stating that it received the "Drug Registration Certificate" for insulin aspart injection approved and issued by the National Medical Products Administration on September 13, 2021.
It was officially approved for production and will be used to treat diabetes.

.
It is understood that insulin is the main type of hypoglycemic drugs on the Chinese market
.
According to statistics, from 2015 to 2019, China's insulin market has grown from 17.
8 billion yuan to nearly 25 billion yuan, accounting for about 46.
3% of the total hypoglycemic drug market
.
In 2020, China's insulin market has reached 28.
6 billion yuan
.
At present, insulin can be divided into first-generation, second-generation, and third-generation insulin
.
In 2019, third-generation insulin accounted for 58% of the entire insulin market share.
Among them, insulin aspart (and its premixed products) and insulin glargine were the third-generation insulin varieties with a larger market share
.
This time, Hisun Pharmaceutical's approved insulin is insulin aspart
.
It is a fast-acting analogue of human insulin designed to control hyperglycemia caused by meals in diabetic patients who require insulin therapy
.
Its hypoglycemic effect is mainly achieved by combining insulin aspart molecules with insulin receptors on muscles and fat cells to promote glucose absorption and inhibit the release of liver glycogen.
Compared with soluble insulin, the subcutaneous absorption rate is faster
.
It is reported that up to now, Hisun Pharmaceutical has invested about 145 million yuan in the research and development project of insulin aspart injection
.
According to the industry, the reason why Hisun Pharmaceuticals has invested heavily in the research and development of insulin aspart is mainly based on the development prospects of the market
.
According to data, the global sales of insulin aspart injection in 2020 will be approximately 7.
439 billion US dollars
.
Among them, the domestic market sales are about 213 million U.
S.
dollars; the global sales from January to March 2021 are about 1.
894 billion U.
S.
dollars, and the domestic market sales are about 63 million U.
S.
dollars
.
Based on the huge market, insulin aspart has become a hot spot in the research and development and production of pharmaceutical companies.
At present, in addition to Hisun Pharmaceutical, Ganli Pharmaceutical, United Laboratories, Yichang Dongyangguang, Tonghua Dongbao, etc.
have also entered the market
.
Among them, Ganli Pharmaceutical is one of the leading local companies.
Public information shows that as early as December 15, 2020, Ganli Pharmaceutical issued an announcement stating that insulin aspart 30 injection has been approved, the first domestically approved one.
Of insulin aspart 30 injection
.
In addition, on July 12 this year, the insulin aspart injection and insulin aspart 30 injection declared by the wholly-owned subsidiary of United Laboratories Zhuhai United Laboratories Co.
, Ltd.
have also passed the drug registration approval of the State Drug Administration
.
The industry believes that as more and more pharmaceutical companies develop insulin products one after another, the competition of insulin companies will become more and more fierce in the future, and the market may usher in major changes
.